Forepont Capital Partners

What is Forepont Capital Partners?

Forepont Capital Partners is a venture capital firm that specializes in healthcare investments, focusing predominantly on the biotech and medtech sectors, including digital health, devices, and diagnostics, both in Europe and the United States. Established in 2017 and headquartered in New York, Forepont has carved a niche in the neurology space, but their interests are not limited to this area.

They typically engage with startups at the seed, pre-Series A, and Series A stages, with investment amounts ranging from $2,000,000 to $15,000,000, with a sweet spot around $5,000,000.

They leverage their deep understanding of the science and an extensive network that includes medical experts and large pharmaceutical companies to provide hands-on support to entrepreneurs.

Forepont is highly selective in their investment approach, avoiding ventures outside healthcare, late-stage companies, or those based in emerging countries. Forepont Capital Partners prides itself on being more than just an investment firm; it's also actively involved in financing cutting-edge medical research, particularly in nerve cell re-myelination (CNS). This research has been a cornerstone of their recognition in the healthcare field since their partners began this journey in 2011.

Their established healthcare partners offer direct access to new investment opportunities, and they meticulously consider medical, human, financial, and ethical aspects before investing. Their strategic approach involves investing in start-ups before they reach an inflection point, providing an opportunity for Forepont’s experience to drive significant value creation.

Additionally, their comprehensive knowledge of American and European regulations helps support portfolio companies. Forepont’s mission encapsulates investing in startups poised to disrupt healthcare and delivering scientific, financial, and operational support to enhance performance and catalyze innovation in pursuit of new treatments that could transform the lives of patients globally.